Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Mar 2026

Tufail Muhammad, Gong Kunxiang, Ijaz Bushra, Patel Harsh, Lui Weng-Onn, Wang Xiumei, Li Jie

Abstract excerpt

Oncogenic signal transduction pathways play pivotal roles in tumor progression by regulating essential cellular processes such as proliferation, survival, angiogenesis, invasion, and immune evasion. These pathways are frequently deregulated in cancer due to genetic mutations, epigenetic modifications, or microenvironmental influences. These genetic or epigenetics shifts enable cancer cells to bypass growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Epigenesis, Genetic

Share to Molecular Targeted Therapy

Share to Neovascularization, Pathologic

Share to Oncogenes

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41546924
DOI: 10.1016/j.drup.2026.101355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.PMID 41546924Read ↗

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.Semantic proximity Read ↗

Oncogenic signaling.Semantic proximity Read ↗

Pro-Oncogenic and Anti-Oncogenic Pathways: Opportunities and Challenges of Cancer TherapySemantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological SignalingSemantic proximity Read ↗

Molecular principles underlying aggressive cancersSemantic proximity Read ↗

Genetic Dysregulation of Immunologic and Oncogenic Signaling Pathways Associated with Tumor-intrinsic Immune Resistance: A Molecular Basis for Combination Targeted Therapy-Immunotherapy for CancerSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.